ClinVar Miner

Submissions for variant NM_001271208.2(NEB):c.1152+1G>A (rs398124167)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000790650 SCV000225853 pathogenic not provided 2013-11-14 criteria provided, single submitter clinical testing
Counsyl RCV000174538 SCV000799429 pathogenic Nemaline myopathy 2 2018-04-18 criteria provided, single submitter clinical testing
Invitae RCV000174538 SCV000956532 pathogenic Nemaline myopathy 2 2018-10-23 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 13 of the NEB gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in combination with another NEB variant in several individuals and families affected with nemaline myopathy (PMID: PMID: 23572184, 25079567, 25205138). ClinVar contains an entry for this variant (Variation ID: 95104). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NEB are known to be pathogenic (PMID: 25205138). For these reasons, this variant has been classified as Pathogenic.
Integrated Genetics/Laboratory Corporation of America RCV001174709 SCV001337975 pathogenic Nemaline myopathy 2020-01-23 criteria provided, single submitter clinical testing Variant summary: NEB c.1152+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 5 splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 1.8e-05 in 219184 control chromosomes (gnomAD). c.1152+1G>A has been reported in the literature in individuals affected with Nemaline Myopathy (e.g. de Winter_2013, Lehtokari_2014). These data indicate that the variant is likely to be associated with disease. Muscle from a patient with the variant exhibited relative deficiency of nebulin protein and lower calcium-sensitivity of force generation and maximal active tension compared to controls (de Winter_2013). Two ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Natera, Inc. RCV000174538 SCV001455523 pathogenic Nemaline myopathy 2 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.